Liposomally targeted cytotoxic drugs for the treatment of cancer

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 12, 2002, Pages 1573-1600

  Harrington, Kevin J ^a   Syrigos, Konstantinos N ^a   Vile, Richard G ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CARDIOLIPIN PLUS PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS DOXORUBICIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DISTEAROYLPHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROGENATED PHOSPHATIDYLINOSITINE PLUS HYDROGENATED PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS DOXORUBICIN; HYDROGENATED SOY PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS MACROGOL DISTEAROYLPHOSPHATIDYLETHANOLAMINE PLUS CISPLATIN; HYDROGENATED SOY PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS MACROGOL DISTEAROYLPHOSPHATIDYLETHANOLAMINE PLUS DOXORUBICIN; LIPOSOME; PACLITAXEL; PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS DOXORUBICIN; PHOSPHATIDYLCHOLINE PLUS OCTADECYLAMINE PLUS CHOLESTEROL PLUS DOXORUBICIN; PHOSPHATIDYLGLYCEROL PLUS DISTEAROYLPHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS INDIUM BLEOMYCIN 111 IN; PHOSPHATIDYLGLYCEROL PLUS PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS ALPHA TOCOPHEROL; PHOSPHATIDYLGLYCEROL PLUS PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS EPIRUBICIN; PHOSPHATIDYLSERINE PLUS PHOSPHATIDYLCHOLINE PLUS CHOLESTEROL PLUS DOXORUBICIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEOPENTANOATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE RESISTANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TUMOR LEVEL; ENCAPSULATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; HYPERTHERMIC THERAPY; HYPOGLYCEMIA; INFECTION; KIDNEY INJURY; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUCOSA TOXICITY; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OTOTOXICITY; PAIN; PERIPHERAL NEUROPATHY; REVIEW; RIGOR; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; SYSTEMIC DISEASE; THORAX PAIN; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; LIPOSOMES; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 0036907725     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357002243     Document Type: Review

References (184)

1. Adlakha-Hutcheon, G., Bally, M. B., Shew, C. R., Madden, T. D. (1999) Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotechnol. 17: 775-779
2. Adler-Moore, J. (1994) AmBisome targeting to fungal infections. Bone Marrow Transplant. 14 (Suppl. 5): S3-S7
3. Allen, T. M., Chonn, A. (1987) Large unilamellar liposomes with low uptake by the reticuloendothelial system. FEBS Lett. 223: 42-46
4. Allen, T. M., Hansen, C. (1991) Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim. Biophys. Acta 1068: 133-141
5. Allen, T. M., Newman, M. S., Woodle, M. C., Mayhew, E., Uster, P. S. (1995) Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer 62: 199-204
6. Bangham, A. D., Standish, H. M., Watkins, J. C. (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13: 238-252
7. Batist, G., Winer, E., Navari, R., Rovira, D., Azarnia, N., TLC D-99 Study Group (1998) Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomised trial of metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. 17: 115a (abstr. 443)
8. Batist, G., Rao, S. C., Ramakrishnan, G. (1999) Phase III study of liposome-encapsulated doxorubicin (TLC D-99) versus doxorubicin (DOX) in combination with cyclophosphamide (CPA) in patients with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 18: 127a (abstr. 486)
9. Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., Patek, A., Martin, F. J. (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. 9: 711-716
10. Bogner, J. R., Kronawitter, U., Rolinski, B., Truebenach, K., Goebel, F.-D. (1994) Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma. J. AIDS 7: 463-468
11. Boman, N. L., Masin, D., Mayer, L. D., Cullis, P. R., Bally, M. B. (1994) Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54: 2830-2833
12. Cabanes, A., Briggs, K. E., Gokhale, P. C., Treat, J. A., Rahman, A. (1998a) Comparative in-vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J. Oncol. 12: 1035-1040
13. Cabanes, A., Tzemach, D., Goren, D., Horowitz, A. T., Gabizon, A. (1998b) Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res. 4: 499-505
14. Caponigro, F., Comella, P., Budillon, A., Bryce, J., Avallone, A., De Rosa, V., Ionna, F., Comella, G. (2000) Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann. Oncol. 11: 339-342
15. Chachoua, A., Green, M., Laubenstein, L., Wernz, J., Muggia, F. M. (1987) Phase II study of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma. Cancer Treat. Rep. 71: 775-776
16. Chang, C. W., Barber, L., Ouyang, C., Masin, D., Bally, M. B., Madden, T. D. (1997) Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilised liposomes after intravenous administration in BDF1 mice. Br. J. Cancer 75: 169-177
17. Cheung, T. W., Remick, S. C., Azarnia, N., Proper, J. A., Barrueco, J. R., Dezube, B. J. (1999) AIDS-related Kaposi's sarcoma: A phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin. Cancer Res. 5: 3432-3437
18. Colbern, G. T., Musterer, R., Hiller, A. J., Pegg, E., Engbers, C., Working, P. K., Henderson, I. C. (1998a) Treatment of palmar-plantar erythrodysaesthesia with pyridoxine or ergotamine: Effect on efficacy of Doxil in Lewis lung carcinoma. Proc. Am. Soc. Clin. Oncol. 17: 238a (abstr. 913)
19. Colbern, G. T., Dykes, D. J., Engbers, C., Musterer, R., Hiller, A., Pegg, E., Saville, R., Weng, S., Luzzio, M., Uster, P., Amantea, M., Working, P. K. (1998b) Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 4: 3077-3082
20. Colbern, G. T., Hiller, A. J., Musterer, R. S., Working, P. K., Henderson, I. C. (1999) Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model. J. Inorg. Biochem. 77: 117-120
21. Cortes, J., O'Brien, S., Estey, E., Giles, F., Keating, M., Kantarjian, H. (1999) Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest. New Drugs 17: 81-87
22. Cortes, J., Estey, E., O'Brien, S., Giles, F., Shen, Y., Koller, C., Beran, M., Thomas, D., Keating, M., Kantarjian, H. (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92: 7-14
23. Cowens, J. W., Creaven, P. J., Greco, W. R., Brenner, D. E., Tung, Y., Ostro, M., Pilkiewicz, F., Ginsberg, R., Petrelli, N. (1993) Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 53: 2796-2802
24. Daniele, B., De Vivo, R., Perrone, F., Lastoria, S., Tambaro, R., Izzo, F., Fiore, F., Vallone, P., Pignata, S. (2000) Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis. Anticancer Res. 20: 1249-1251
25. DeMario, M. D., Vogelzang, N. J., Janisch, L., Tonda, M., Amantea, M. A., Pendyala, L., Ratain, M. J. (1998) A phase I study of liposome-formulated cisplatin (SPI-77®) given every 3 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 17: 230a (abstr. 883)
26. DeVore, R. F., Johnson, D. H., Strupp, J., Krozely, P., Hunt, G., Tonda, M., Wilson, C. (1999) Phase I trial of SPI-077 plus paclitaxel in patients with refractory non-small cell lung cancer (NSCLC) Proc. Am. Soc. Clin. Oncol. 18: 488a (abstr. 1881)
27. Durocher, J. R., Payne, R. C., Conrad, M. E. (1975) Role of sialic acid in erythrocyte survival. Blood 45: 11-20
28. Dvorak, J., Zoul, Z., Melichar, B., Jandik, P., Mergancova, J., Hrncirova, I., Urminska, H., Petera, J. (2001) Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: A case report. Onkologie 24: 166-168
29. Elson, P., Chidiac, T., Budd, G. T., Pelley, R., Sandstrom, K., McLain, D., Crownover, R., Marks, K., Muschler, G., Zehr, R., Joyce, M., Bukowski, R. (1998) Phase II trial of Doxil in advanced soft tissue sarcomas (STS) Proc. Am. Soc. Clin. Oncol. 17: 513a (abstr. 1979)
30. Embree, L., Gelmon, K. A., Lohr, A., Mayer, L. D., Coldman, A. J., Cullis, P. R., Palaitis, W., Pilkiewicz, F., Hudon, N. J., Heggie, J. R. (1993) Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non small-cell lung cancer patients. J. Pharm. Sci. 82: 627-634
31. Emerson, D. L., Bendele, R., Brown, E., Chiang, S., Desjardins, J. P., Dihel, L. C., Gill, S. C., Hamilton, M., LeRay, J. D., Moon-McDermott, L., Moynihan, K., Richardson, F. C., Tomkinson, B., Luzzio, M. J., Baccanari, D. (2000) Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. 6: 2903-2912
32. Fischl, M. A., Krown, S. E., O'Boyle, K. P., Mitsuyasu, R., Miles, S., Wernz, J. C., Volberding, P. A., Kahn, J., Groopman, J. E., Feinberg, J. (1993) Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J. AIDS 6: 259-264
33. Forssen, E. A., Ross, M. E. (1994) DaunoXome® treatment of solid tumours; Preclinical and clinical investigations. J. Liposome Res. 4: 481-512
34. Forssen, E. A., Tokes, Z. A. (1983) Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 43: 546-550
35. Forssen, E. A., Coulter, D. M., Proffitt, R. T. (1992) Selective in-vivo localisation of daunorubicin small unilamellar vesicles in solid tumours. Cancer Res. 52: 3255-3261
36. Forssen, E. A., Krasieva, T. B., Shimizu, S., Tromberg, B. J.. (1996) Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue. Cancer Res. 56: 2066-2075
37. Gabizon, A. A. (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52: 891-896
38. Gabizon, A. A. (1994) Liposomal anthracyclines. Hematol. Oncol. Clin. North Am. 8: 431-450
39. Gabizon, A., Papahadjopoulos, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumours. Proc. Natl Acad. Sci. USA 85: 6949-6953
40. Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., Fuks, Z. (1982) Liposomes as in-vivo carriers of adriamycin: Reduced cardiac uptake and preserved antitumour activity in mice. Cancer Res. 42: 4734-4739
41. Gabizon, A., Goren, D., Fuks, Z., Barenholz, Y., Dagan, A., Meshorer, A. (1983) Enhancement of adriamycin delivery to liver metastatic cells with increased tumouricidal effect using liposomes as drug carriers. Cancer Res. 43: 4730-4735
42. Gabizon, A., Goren, D., Fuks, Z., Meshorer, A., Barenholz, Y. (1985) Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br. J. Cancer 51: 681-689
43. Gabizon, A., Meshorer, A., Barenholz, Y. (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl Cancer Inst. 77: 459-469
44. Gabizon, A., Shiota, R., Papahadjopoulos, D. (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl Cancer Inst. 81: 1484-1488
45. Gabizon, A., Price, D. C., Huberty, J., Bresalier, R. S., Papahadjopoulos, D. (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumours: Biodistribution and imaging studies. Cancer Res. 50: 6371-6378
46. Gabizon, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I., Peretz, T., Sulkes, A., Barenholz, Y. (1991) Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64: 1125-1132
47. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., Barenholz, Y. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polethylene-glycol coated liposomes. Cancer Res. 54: 987-992
48. Gelmon, K. A., Tolcher, A., Diab, A. R., Bally, M. B., Embree, L., Hudon, N., Dedhar, C., Ayers, D., Eisen, A., Melosky, B., Burge, C., Logan, P., Mayer, L. D. (1999) Phase I study of liposomal vincristine. J. Clin. Oncol. 17: 697-705
49. Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., Levine, A. M. (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13: 996-1003
50. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., Von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., Rarick, M. U., Myers, A. M., Shepherd, F., Sawka, C., Pike, M. C., Ross, M. E. (1996) Randomised phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14: 2353-2364
51. Girard, P. M., Bouchaud, O., Goetschel, A., Mukwaya, G., Eestermans, G., Ross, M., Rozenbaum, W., Saimot, A. G. (1996) Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 10: 753-757
52. Goebel, F.-D., Goldstein, D., Goos, M., Jablonowski, H., Stewart, J. S. (1996) Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer 73: 989-994
53. Gokhale, P. C., Radhakrishnan, B., Husain, S. R., Abernethy, D. R., Sacher, R., Dritschilo, A., Rahman, A. (1996) An improved method of encapsulation of doxorubicin in liposomes: Pharmacological, toxicological and therapeutic evaluation. Br. J. Cancer 74: 43-48
54. Gondal, J. A., Preuss, H. G., Swartz, R., Rahman, A. (1993) Comparative pharmacological, toxicological and antitumoural evaluation of free and liposome-encapsulated cisplatin in rodents. Eur. J. Cancer 29A: 1536-1542
55. Gordon, K. B., Tajuddin, A., Guitart, J., Kuzel, T. M., Eramo, L. R., Von Roenn, J. (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75: 2169-2173
56. Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., Sharpington, T. (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18: 3093-3100
57. Gregoriadis, G. (1976a) The carrier potential of liposomes in biology and medicine (first of two parts). N. Engl. J. Med. 295: 704-710
58. Gregoriadis, G. (1976b) The carrier potential of liposomes in biology and medicine (second of two parts). N. Engl. J. Med. 295: 765-770
59. Gregoriades, G., Swain, C. P., Wills, E. J., Tavill, A. S. (1974) Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1: 1313-1316
60. Halford, S., Yip, D., Karapetis, C. S., Strickland, A. H., Steger, A., Khawaja, H. T., Harper, P. G. (2001) A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann. Oncol. 12: 1399-1402
61. Halm, U., Etzrodt, G., Schiefke, I., Schmidt, F., Witzigmann, H., Mossner, J., Berr, F. (2000) A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann. Oncol. 11: 113-114
62. Harasym, T. O., Cullis, P. R., Bally, M. B. (1997) Intratumour distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol. 40: 309-317
63. Harrington, K. J., Rowlinson-Busza, G., Uster, P. S., Whittaker, J., Stewart, J. S. W. (1998) Stealth liposome encapsulated doxorubicin (SLED) and iododeoxyuridine (SLIUDR) as radiation sensitisers in head and neck squamous cell cancer xenograft tumours (HNSCCXT). Proc. Am. Soc. Clin. Oncol. 17: 230a (abstr. 881)
64. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: Implications for novel targeting strategies. Br. J. Cancer 83: 232-238
65. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br. J. Cancer 83: 684-688
66. Harrington, K. J., Rowlinson-Busza, G., Uster, P. S., Stewart, J. S. (2000c) Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother. Pharmacol. 46: 10-18
67. Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., Stewart, J. S. W. (2001a) Effective targeting of solid tumours in patients with locally advanced cancers by radiolabelled pegylated liposomes. Clin. Cancer Res. 7: 243-254
68. Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Vile, R. G., Peters, A. M., Stewart, J. S. W. (2001b) Phase II study of pegylated liposomal doxorubicin (Caelyx™) in patients with inoperable, locally advanced squamous cell cancer of the head and neck. Eur. J. Cancer 37: 2015-2022
69. Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., Stewart, J. S. W. (2001c) Phase I/II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer. Ann. Oncol. 12: 493-496
70. Harris, L., Winer, E., Batist, G., Rovira, D., Navari, R., Lee, L., (1998) Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (Dox) in patients with metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. 17: 124a (abstr. 474)
71. Harrison, M., Tomlinson, D., Stewart, S. (1995) Liposomal entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 13: 914-920
72. Hengge, U. R., Brockmeyer, N. H., Baumann, M., Reimann, G., Goos, M. (1993) Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 343: 497
73. Hong, R. L., Huang, C. J., Tseng, Y. L., Pang, V. F., Chen, S. T., Liu, J. J., Chang, F. H. (1999) Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5: 3645-3652
74. Huang, S. K., Mayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., Papahadjopoulos, D. (1992a) Pharmacokinetics and therapeutics of sterically stabilised liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52: 6774-6781
75. Huang, S. K., Lee, K.-D., Hong, K., Friend, D. S., Papahadjopoulos, D. (1992b) Microscopic localisation of sterically stabilised liposomes in colon carcinoma-bearing mice. Cancer Res. 52: 5135-5143
76. Huang, S. K., Martin, F. J., Jay, G., Vogel, J., Papahadjopoulos, D., Friend, D. S. (1993) Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIVtat gene. Am. J. Pathol. 143: 1-14
77. Ishida, O., Maruyama, K., Sasaki, K., Iwatsuru, M. (1999) Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm. 190: 49-56
78. Israel, V. K., Jeffers, S., Bernal, G., Rueda, G., Roman, L., Roman, C. P., Rosales, R., Amantea, M., Muggia, F. M. (1998) Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel. Proc. Am. Soc. Clin. Oncol. 17: 245a (abstr. 938)
79. Israel, V. P., Garcia, A. A., Roman, L., Muderspach, L., Burnett, A., Jeffers, S., Muggia, F. M. (2000) Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol. Oncol. 78: 143-147
80. James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R., Gompels, M., Pinching, A. J., Stewart, J. S. (1994) Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol. (R. Coll. Radiol.) 6: 294-296
81. Johnston, S. R., Gore, M. E. (2001) Caelyx: Phase II studies in ovarian cancer. Eur. J. Cancer 37; S8-S14
82. Judson, I., Radford, J. A., Harris, M., Blay, J. Y., Van Hoesel, Q., Le Cesne, A., Van Oosterom, A. T., Clemons, M. J., Kamby, C., Hermans, C., Whittaker, J., Donato Di Paola, E., Verweij, J., Nielsen, S. (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37: 870-877
83. Kaplan, L., Volberding, P. A. (1985) Failure (and danger) of mitozantrone in AIDS-related Kaposi's sarcoma. Lancet 2: 396
84. Khalifa, A., Dodds, D., Rampling, R., Paterson, J., Murray, T. (1997) Liposomal distribution in malignant glioma: Possibilities for therapy. Nucl. Med. Commun. 18: 17-23
85. Khokhar, A. R., Wright, K., Siddik, Z. H., Perez-Soler, R. (1988) Organ distribution and tumour uptake of liposome entrapped cis-bis-neodecanoato trans-R,R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother. Pharmacol. 22: 223-227
86. Khokhar, A. R., Al-Baker, S., Krakoff, I. H., Perez-Soler, R. (1989) Toxicity and antitumour activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes. Cancer Chemother. Pharmacol. 23: 219-224
87. Klein, P., Lyass, O., Sorich, J. (1998) Doxil plus cisplatin: Combined results of two Phase I studies. Proc. Am. Soc. Clin. Oncol. 17: 246a (abstr. 942)
88. Klibanov, A. L., Maruyama, K., Torchilin, V. P., Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation times of liposomes. FEBS Lett. 268: 235-237
89. Konno, H., Yamashita, A., Tadakuma, T., Sakaguchi, S. (1991) Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Antitumour effect of IL-2 liposome. Biotherapy 3: 211-218
90. Koshkina, N. V., Kleinerman, E. S., Waidrep, C., Jia, S. F., Worth, L. L., Gilbert, B. E., Knight, V. (2000) 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. 6: 2876-2880
91. Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S. C., Skarlatos, J., Beroukas, K., Bizakis, J. G., Retalis, G., Karkavitsas, N., Helidonis, E. S. (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 17: 3512-3521
92. Kouloulias, V. E., Dardoufas, C. E., Kouvaris, J. R., Gennatas, C. S., Polyzos, A. K., Gogas, H. J., Sandilos, P. H., Uzunoglu, N. K., Malas, E. G., Vlahos, L. J. (2002) Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: A phase I/II trial. Clin. Cancer Res. 8: 374-382
93. Kubo, A., Nakamura, K., Sammiya, T., Katayama, M., Hashimoto, T., Hashimoto, S., Kobayashi, H., Teramoto, T. (1993) Indium-111-labelled liposomes: Dosimetry and tumour detection in patients with cancer. Eur. J. Nucl. Med. 20: 107-113
94. Langley, R. E., Carmichael, J., Woll, P. J., Mason, E., Welbank, H. (1998) Phase II trial to evaluate the safety and tolerability of Caelyx® in combination with paclitaxel in the treatment of metastatic cancer. Proc. Am. Soc. Clin. Oncol. 17: 246a (abstr. 943)
95. Lasic, D. D. (1996) Doxorubicin in sterically stabilised liposomes. Nature 380: 561-562
96. Lasic, D. D., Papahadjopoulos, D. (1995) Liposomes revisited. Science 267: 1275-1276
97. Laufman, L. R., Spiridonidis, C. H., Jones, J. J., Rhodes, V. A., Wallace, K. (1998) Phase I trial of Doxil® plus vinorelbine (VNB) in patients (PTS) with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 17: 246a (abstr. 944)
98. Leyland-Jones, B. (1993) Targeted drug delivery. Semin. Oncol. 20: 12-17
99. Lippens, R. J. (1999) Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors. Pediatr. Hematol. Oncol. 16: 131-139
100. Lopez, A. M., Wallace, L., Dorr, R. T., Koff, M., Hersh, E. M., Alberts, D. S. (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother. Pharmacol. 44: 303-306
101. Lotem, M., Hubert, A., Lyass, O., Goldenhersh, M. A., Ingber, A., Peretz, T., Gabizon, A. (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 136: 1475-1480
102. Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., Gabizon, A. (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89: 1037-1047
103. Madhavan, S., Northfelt, D. W. (1995) Lack of vesicant injury following extravasation of liposomal doxorubicin. J. Natl Cancer Inst. 87: 1556-1557
104. Malik, S. T., Martin, D., Hart, I., Balkwill, F. (1991) Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. Br. J. Cancer 63: 399-403
105. Malik, U. R., Sparano, J. A., Wolffe, A. (1998) Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (PTS) with advanced breast cancer (ABC) Proc. Am. Soc. Clin. Oncol. 17: 175a (abstr. 672)
106. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78: 369-372
107. Martin, F. J. (1997) Pegylated liposomal doxorubicin: Scientific rationale and preclinical pharmacology. Oncology 11 (Suppl. 11): 11-20
108. Mavroudis, D., Kouroussis, C., Kakolyris, S., Agelaki, S., Kalbakis, K., Androulakis, N., Souglakos, J., Samonis, G., Georgoulias, V. (2002) Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors. Oncology 62; 216-222
109. Mayer, L. D., Bally, M. B., Loughrey, H., Masin, D., Cullis, P. R. (1990) Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 50: 575-579
110. Mayhew, E. G., Goldrosen, M. H., Vaage, J., Rustum, Y. M. (1987) Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J. Natl Cancer Inst. 78: 707-713
111. Mayhew, E. G., Lasic, D., Babbar, S., Martin, F. J. (1992) Pharmacokinetics and antitumour activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int. J. Cancer 51: 302-309
112. Money-Kyrle, J. F., Bates F., Ready, J., Gazzard, B. G., Phillips, R. H., Boag, F. C. (1993) Liposomal daunorubicin in advanced Kaposi's sarcoma: A phase II study. Clin. Oncol. (R. Coll. Radiol.) 5: 367-371
113. Mori, A., Wu, S. P., Han, I., Khokhar, A. R., Perez-Soler, R., Huang, L. (1996) In-vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother. Pharmacol. 37: 435-444
114. Muggia, F., Hamilon, A. (2001) Phase III data on Caelyx in ovarian cancer. Eur. J. Cancer 37 (Suppl. 9): S15-S18
115. Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., Burnett, A., Greco, F. A., Morrow, C. P., Paradiso, L. J., Liang, L. J. (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15: 987-993
116. Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., Amantea, M. A. (1999) Comparative pharmacokinetics, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumour-bearing mice. Cancer Chemother. Pharmacol. 43: 1-7
117. Ng, T. T., Denning, D. W. (1995) Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch. Intern. Med. 155: 1093-1098
118. Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., Kaplan, L. D. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumour localisation, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36: 55-63
119. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl M. A., Friedman-Kien A., Kaplan L. D., Du Mond C., Mamelok, R. D., Henry, D. H. (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomised phase III clinical trial. J. Clin. Oncol. 16: 2445-2451
120. O'Brien, M., Hickish, T., Iveson, T., Gilligan, D., Harper, P., Light, L., Whittaker, J., Smith, I. E. (1998) Phase II study of Caelyx® (Doxil®; Doxorubicin HCl pegylated liposomal) in the treatment of small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 17: 497a (abstr. 1913)
121. O'Byrne, K. J., Thomas, A. L., Sharma, R. A., DeCatris, M., Shields, F., Beare, S., Steward, W. P. (2002) A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br. J. Cancer 87; 15-20
122. Ogihara-Umeda, I., Sasaki, T., Kojima, S., Nishigori, H. (1996) Optimal radiolabelled liposomes for tumour imaging. J. Nucl. Med. 37: 326-332
123. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C. (1991) Sterically stabilised liposomes: Improvements in pharmacokinetics and anti-tumour therapeutic efficacy. Proc. Natl Acad. Sci. USA 88: 11460-11464
124. Pennington, K., Gordon, M., Picus, J. (1998) A phase II trial of liposomal doxorubicin (Doxil®) in the treatment of advanced renal cell cancer: A Hoosier Oncology Group (HOG) study. Proc. Am. Soc. Clin. Oncol. 17: 339a (abstr. 1308)
125. Perez-Soler, R. (1989) Liposomes as carriers of antitumour agents: Toward a clinical reality. Cancer Treat. Rev. 16: 67-82
126. Perez-Soler, R., Khokhar, A. R., Lopez-Berenstein, G. (1987) Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato trans-R,R-1,2 diaminocyclohexane platinum (II) entrapped in multilamellar vesicles. Cancer Res. 47: 6462-6466
127. Perez-Soler, R., Young, L. Y., Drewinko, B., Lautersztain, J., Khokhar, A. R. (1988) Increased cytotoxicity and reversal of resistance to cisplatin with entrapment of cis-bis-neodecanoato trans-R,R-1,2 diaminocyclohexane platinum (II) in multilamellar vesicles. Cancer Res. 48: 4509-4512
128. Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., Al-Baker, S., Francis, K., Macias-Kiger, D., Raber, M. N., Khokhar, A. R. (1990) Phase I clinical and pharmacology study of liposome-entrapped cis-bis-neodecanoato trans-R,R-1,2 diaminocyclohexane platinum (II) Cancer Res. 50: 4254-4259
129. Perez-Soler, R., Shin, D. M., Siddik, Z. H., Murphy, W. K., Huber, M., Lee, S. J., Khokhar, A. R., Hong, W. K. (1997) Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin. Cancer Res. 3: 373-379
130. Perez-Soler, R., Walsh, G. L., Swisher, S. G. (1999) Phase II study of liposome-entrapped cisplatin-analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 18: 421a (abstr. 1626)
131. Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., Stevens, R. F., Darbyshire, P. J., Gibson, B. E. (1997) A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98: 711-718
132. Presant, C. A., Proffitt, R. T., Turner, A. F., Williams, L. E., Winsor, D., Werner, J. L., Kennedy, P., Wiseman, C., Gala, K., McKenna, R. J. (1988) Successful imaging of human cancer with Indium-111-labelled phospholipid vesicles. Cancer 62: 905-911
133. Presant, C. A., Blayney, D., Proffitt, R. T., Turner, A. F., Williams, L. E., Nadel, H. I., Kennedy, P., Wiseman, C., Gala, K., Crossley, R. J. (1990) Preliminary report: Imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet 335: 1307-1309
134. Presant, C. A., Scolaro, M., Kennedy, P., Blayney, D. W., Flanagan, B., Lisak, J., Presant, J. (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242-1243
135. Proffitt, R. T., Williams, L. E., Presant, C. A., Tin, G. W., Uliana, J. A., Gamble, R. C., Baldeschwieler, J. D. (1983) Tumour-imaging potential of liposomes loaded with In-111-NTA: Biodistribution in mice. J. Nucl. Med. 24: 45-51
136. Rahman, A., Kessler, A., More, N., Sikic, B., Rowden, G., Woolley, P., Schein, P. S. (1980) Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 40: 1532-1537
137. Ramirez, M. R., Marcom, P. K., Sutton, L. M., Harris, L. N., Petros, W. P., Berry, D. A., Warmuth, M. A., Winer, E. P. (1998) A phase I/II study of Doxil and vinorelbine in metastatic breast cancer patients. Proc. Am. Soc. Clin. Oncol. 17: 169a (abstr. 650)
138. Ranson, M. R., Carmichael, J., O'Byrne, K., Stewart, S., Smith, D., Howell, A. (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicentre phase II trial. J. Clin. Oncol. 15, 3185-3191
139. Richardson, V. J., Ryman, B. E., Jewkes, R. F., Jeyasingh, K., Tattersall, M. N., Newlands, E. S., Kaye, S. B. (1979) Tissue distribution and tumour localisation of 99m-technetium-labelled liposomes in cancer patients. Br. J. Cancer 40: 35-43
140. Rudolph, R., Stein, R. S., Pattillo, R. A. (1976) Skin ulcers due to adriamycin. Cancer 38: 1087-1094
141. Russo, R., Nigro, L. C., Minniti, S. (1996) Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome) J. Infect. 32: 133-137
142. Sarris, A. H., Hagemeister, F., Romaguera, J., Rodriguez, M. A., McLaughlin, P., Tsimberidou, A. M., Medeiros, L. J., Samuels, B., Pate, O., Oholendt, M., Kantarjian, H., Burge, C., Cabanillas, F. (2000) Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Ann. Oncol. 11: 69-72.
143. Schwonzen, M., Kurbacher, C. M., Mallmann, P. (2000) Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 11: 681-685
144. Senior, J., Gregoriadis, G. (1982a) Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett. 145: 109-114
145. Senior, J., Gregoriadis, G. (1982b) Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. Life Sci. 30: 2123-2136
146. Sessa, G., Weissmann, G. (1968) Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res. 9: 310-318
147. Shapiro, C. L., Ervin, T., Welles, T., Azarnia, N., Keating, J., Hayes, D. F. (1999) Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J. Clin. Oncol. 17: 1435-1441
148. Shepherd, F. A., Burkes, R., Paul, K. E., Gross, P. E. (1991) A phase II study of 4′-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS. AIDS 5: 305
149. Sheilds, A. F., Lange, L. M., Zalupski, M. M. (2001) Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. Am. J. Clin. Oncol. 24; 96-98
150. Siegal, T., Horowitz, A., Gabizon, A. (1995) Doxorubicin encapsulated in sterically stabilised liposomes for the treatment of a brain tumour model: Biodistribution and therapeutic efficacy. J. Neurosurg. 83: 1029-1037
151. Simpson, J. K., Miller, R. F., Spittle, M. F. (1993) Liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Clin. Oncol. (R. Coll. Radiol.) 5: 372-374
152. Skubitz, K. M. (1998) Early results of pegylated liposomal doxorubicin (Doxil®) in refractory sarcoma. Proc. Am. Soc. Clin. Oncol. 17: 524a (abstr. 2013)
153. Speyer, J., Wasserheit, C. (1998) Strategies for reduction of anthracycline cardiac toxicity. Semin. Oncol. 25: 525-537
154. Steele, J. P., O'Doherty, C. A., Shamash, J., Evans, M. T., Gower, N. H., Tischkowitz, M. D., Rudd, R. M. (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann. Oncol. 12: 497-499
155. Steerenberg, P. A., Storm, G., De Groot, G., Claessen, A., Bergers, J. J., Franken, M. A., Van Hoesel, Q. G., Wubs, K. L., De Jong, W. H. (1988) Liposomes as drug carrier system for cis-diammine-dichloroplatinum (II) II. Antitumour activity in-vivo, induction of drug resistance, nephrotoxicity and Pt distribution. Cancer Chemother. Pharmacol. 21: 299-307
156. Stewart, S., Jablonowski, H., Goebel, F.-D., Arasteh, K., Spittle, M., Rios, A., Aboulafia, D., Galleshaw, J., Dezube, B. J. (1998) Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. 169: 683-691
157. Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., Gabizon, A. (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86: 72-78
158. Thomas, A. L., O'Byrne, K., Furber, L., Jeffery, K., Steward, W. P. (2001) A phase II study of caelyx, liposomal doxorubicin: Lack of activity in patients with advanced gastric cancer. Cancer Chemother. Pharmacol. 48: 266-268.
159. Toma, S., Tucci, A., Villani, G., Carteni, G., Spadini, N., Palumbo, R. (2000) Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A phase II study of the Italian Sarcoma Group (ISG) Anticancer Res. 20: 485-491
160. Tsiara, S. N., Kapsali, E., Christou, L., Panteli, A., Pritsivelis, N., Bourantas, K. L. (2000) Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: Preliminary data. Eur. J. Haematol. 65: 118-122
161. Turner, A. F., Presant, C. A., Proffitt, R. T., Williams, L. E., Winsor, D. W., Werner, J. L. (1988) In-111-labelled liposomes: Dosimetry and tumour depiction. Radiology 166: 761-765
162. Uthayakumar, S., Bower, M., Money-Kyrle, J., Muyshondt, C., Youle, M., Hannon, F., Phillips, R., Gazzard, B. G., Boag, F. (1996) Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 10: 515-519
163. Vaage, J., Mayhew, E., Lasic, D., Martin, F. (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 51: 942-948
164. Vaage, J., Donovan, D., Mayhew, E., Uster, P., Woodle, M. (1993a) Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilised liposomes. Int. J. Cancer 54: 959-964
165. Vaage, J., Donovann, D., Mayhew, E., Abra, R., Huang, A. (1993b) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilised liposomes. Cancer 72: 3671-3675
166. Vaage, J., Barbera-Guillem, F., Abra, R., Huang, A., Working, P. (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73: 1478-1484
167. Vaage, J., Donovan, D., Loftus, T., Working, P. (1995) Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br. J. Cancer 72: 1074-1075
168. Vaage, J., Donovan, D., Uster, P., Working, P. (1997) Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br. J. Cancer 75: 482-486
169. Vaage, J., Donovan, D., Wipff, E., Abra, R., Colbern, G., Uster, P., Working, P. (1999) Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int. J. Cancer 80: 134-137
170. Vadiei, K., Siddik, Z. H., Khokhar, A. R., Al-Baker, S., Sampedro, F., Perez-Soler, R. (1992) Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato trans-R,R-1,2 diaminocyclohexane platinum (II) and cisplatin given i.v. and i. p. in the rat. Cancer Chemother. Pharmacol. 30: 365-369
171. Vail, D. M., Chun, R., Thamm, D. H., Garrett, L. D., Cooley, A. J., Obradovich, J. E. (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin. Cancer Res. 4: 1567-1571
172. Valero, V., Buzdar, A. U., Theriault, R. L., Azarnia, N., Fonseca, G. A., Willey, J., Ewer, M., Walters, R. S., Mackay, B., Podoloff, D., Booser, D., Lee, L. W., Hortobagyi, G. N. (1999) Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J. Clin. Oncol. 17: 1425-1434
173. Van Hoesel, Q. G., Steerenberg, P. A., Crommelin, D. J., Van Dijk, A., Van Oort, W., Klein, S., Douze, J. M., De Wildt, D. J., Hillen, F. C. (1984) Reduced cardiotoxicity and nephrotoxicity with preservation of anti-tumour activity of doxorubicin entrapped in stable liposomes in the LIEU/M Wsl rat. Cancer Res. 44: 3698-3703
174. Verschraegen, C. F., Gilbert, B. E., Huaringa, A. J., Newman, R., Harris, N., Leyva, F. J., Keus, L., Campbell, K., Nelson-Taylor, T., Knight, V. (2000) Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann. N. Y. Acad. Sci. 922: 352-354
175. Von Hoff, D. D., Layard, M. W., Basa, P. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91: 710-717
176. Webb, M. S., Harasym, T. O., Masin, D., Bally, M. B., Mayer, L. D. (1995) Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72: 896-904
177. Williams, S. S., Alosco, T. R., Mayhew, E., Lasic, D. D., Martin, F. J., Bankert, R. B. (1993) Arrest of human lung tumour xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilised liposomes. Cancer Res. 53: 3964-3967
178. Winer, E., Batist, G., Belt, R., Gutheil, J., Parki, Y., Wells, L. (2000) Reduced cardiotoxicity of liposome-encapsulated doxorubicin (TLC D-99) compared to free doxorubicin in first-line therapy of metastatic breast cancer in patients at increased risk for anthracycline-induced cardiac toxicity. Proc. Am. Soc. Clin. Oncol. 19: 64a (abstr. 323)
179. Wollina, U., Graefe, T., Karte, K. (2000) Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J. Am. Acad. Dermatol. 42: 40-46
180. Wollina, U., Graefe, T., Kaatz, M. (2001) Pegylated doxorubicin for primary cutaneous T-cell lymphoma: A report on ten patients with follow-up. J. Cancer Res. Clin. Oncol. 127: 128-134
181. Yeo, W., Chann, K. K., Mukwaya, G., Ross, M., Leung, W. T., Ho, S., Chan, A. T., Johnson, P. J. (1999) Phase II studies with DaunoXome in patients with non-resectable hepatocellular carcinoma: Clinical and pharmacokinetic outcomes. Cancer Chemother. Pharmacol. 44: 124-130
182. Yip, D., Halford, S., Karapetis, C., Steger, A., Khawaja, H., Harper, P. (1999) A phase II trial of Caelyx™ (liposomal doxorubicin, Doxil™) in the treatment of advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 18: 306a (abstr. 1177)
183. Zalipsky, S., Qazen, M., Walker, J. A., Mullah, N., Quinn, Y. P., Huang, S. K. (1999) New detachable poly(ethylene glycol) conjugates: Cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem. 10: 703-707
184. Zucchetti, M., Boiardi, A., Silvani, A., Parisi, I., Piccolrovazzi, S., D'Incalci, M. (1999) Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother. Pharmacol. 44: 173-176